Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Investment analysts at Leerink Swann lowered their Q3 2018 earnings estimates for shares of Endo International in a research note issued on Monday, October 15th, according to Zacks Investment Research. Leerink Swann analyst A. Fadia now anticipates that the company will post earnings of $0.57 per share for the quarter, down from their prior estimate of $0.58. Leerink Swann currently has a “Market Perform” rating and a $18.00 target price on the stock. Leerink Swann also issued estimates for Endo International’s FY2018 earnings at $2.53 EPS, FY2019 earnings at $2.92 EPS, FY2020 earnings at $2.66 EPS, FY2021 earnings at $2.81 EPS and FY2022 earnings at $2.50 EPS.
ENDP has been the subject of several other reports. Deutsche Bank set a $11.00 price target on shares of Endo International and gave the stock a “buy” rating in a report on Wednesday, July 18th. ValuEngine upgraded shares of Endo International from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 25th. BidaskClub downgraded shares of Endo International from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Morgan Stanley upped their price target on shares of Endo International from $7.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, August 17th. Finally, Zacks Investment Research downgraded shares of Endo International from a “buy” rating to a “hold” rating in a report on Tuesday, September 18th. Fifteen research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $14.91.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The firm had revenue of $714.70 million during the quarter, compared to analysts’ expectations of $679.72 million. During the same period in the prior year, the company earned $0.93 earnings per share. The company’s quarterly revenue was down 18.4% on a year-over-year basis.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after purchasing an additional 284,599 shares during the period. New York State Teachers Retirement System grew its holdings in Endo International by 27.0% during the 2nd quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock worth $3,366,000 after acquiring an additional 75,844 shares during the period. Diamond Hill Capital Management Inc. grew its holdings in Endo International by 1.0% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,100,259 shares of the company’s stock worth $10,375,000 after acquiring an additional 10,600 shares during the period. Sivik Global Healthcare LLC acquired a new stake in Endo International during the 2nd quarter worth about $1,697,000. Finally, Schroder Investment Management Group grew its holdings in Endo International by 78.1% during the 2nd quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock worth $7,349,000 after acquiring an additional 327,775 shares during the period. Institutional investors and hedge funds own 98.43% of the company’s stock.
In related news, Director Roger H. Kimmel sold 26,074 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.80% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.